1. Article | 2020.07.07

   Modeling human SARS-CoV-2 infection in mice with human lung xenografts

   To date there is no specific therapeutic treatment or vaccine for COVID-19 caused by the SARS-CoV-2 virus and relevant animal models that mimic human COVID-19 pathologies are lacking. We will generate two novel humanized mouse models: HuLung mice (human lung) and HIS-HuLung mice (and human immune system and human lung). Infection of HuLung and HIS-HuLung mice with SARS-CoV-2 will provide an in...

2. Article | 2020.07.07

   Neurological implications of SARS-COV-2 infection – a transversal study

   Aim: The infection of the nasal mucosa and the lungs by CoV-2 may spread to the CNS, including the brainstem, thereby playing a potential key role in the severe respiratory distress observed in COVID-19. Although several clinical observations support this hypothesis, the knowledge in this field is very limited. To fill this gap, we will investigate CoV-2 neuroinvasion in humans, animal models,...

3. Report | 2022.07.08

   A historic fight against emerging infectious diseases

   Emerging infectious diseases result from contact between microbes and animals, with humans the most parasitized animal species. From the plague in Asia in 1894 to the current COVID-19 crisis, scientists at the Institut Pasteur have long leveraged their expertise and talent to further knowledge creation and benefit humankind.

4. News | 2022.04.14

   Monoclonal antibody SPK001: potent and broad neutralization activity across all SARS-CoV-2 variants of concern

   SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm),...

5. Document de presse | 2021.08.19

   Immune checkpoint inhibitors improve cellular immunity against SARS-CoV-2

   Researchers and doctors from the AP-HP, the Institut Pasteur, the University of Paris and the Sorbonne University, have carried out work on the effect of immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) on cellular immunity against SARS-CoV-2. This work, the results of which suggest that these treatments are not deleterious during infection with COVID-19 and, on the contrary, seem to...

6. Article | 2020.06.16

   Household transmission investigation study for SARS in overseas territories

   Aim: EPI-COVID-19, a research project in epidemiology to study intra-household transmission around cases of Covid-19 confirmed in French Guiana.The EPI-COVID study, covering 250 households (150 in French Guiana, 50 in Guadeloupe and 50 in New Caledonia), should make it possible to investigate the secondary infection rate, the speed of spread of the virus, the proportion of asymptomatic cases...

7. Page avancée | 2016.09.19

   Pasteur courses old

   Due to the exceptional circumstances of the Covid-19 health crisis,we are obliged to cancel all Pasteur courses until July 2020 (included).Registrations for Pasteur courses from September 2020 will be open in few days.We apologize for this rescheduling and are waiting for you in our Education Center at the start of the 2020 academic year.With sessions on theory and hands-on practicals, the...

8. Article | 2020.06.16

   Generation of animal models sensitive to SARS-CoV-2 to test vaccines or drugs

   Aim: Rapid development of animal models is of utmost importance to test the efficacy of vaccines and drug against COVID-19. The aim of this research project is to propose models whose cells express the human ACE2 proteins (huACE2) so that they are sensitive to SARS-CoV-2. The ACE2 protein is the gateway for the virus to enter cells. Researchers are proposing to use adenoviruses and...

9. Article | 2020.06.16

   Descriptive study: epidemiological, clinical and immunological analysis of SARS-CoV-2 cases in the Metropolitan Region of São Paulo, Brazil

   Aim: to identify and analyze the profile of people infected with the SARS-CoV-2 virus in São Paulo, Brazil. This project will be conducted in the Metropolitan Region of São Paulo, one of the most densely populated areas in the world, where the contact rate is accordingly high. By studying epidemiological, clinical and serological aspects of infected individuals, this work will supplement...

10. Article | 2020.06.22

    Urgent Discovery of Drug Candidates That Target Coronavirus SARS-CoV-2

    Aim: rapidly provide drug candidates to treat victims of Covid-19. We will do this by applying our cutting-edge technologies and libraries to screen for viable active compounds that kill coronavirus. The strategy will employ phenotype screens (FPDD) that test for coronavirus inhibition using mouse (MHV-59) and human (OC43) virus as models for fast compound screening in cell culture. Direct-...

Pages